MOLECULAR PARTNERS AG MEDIA RELEASE
Molecular Partners' R&D Day in New York highlights progress of pipeline of DARPin® therapeutic candidates and dedicated research focus areas
- The company announces plans to launch a second phase 2 clinical trial in multiple myeloma with MP0250, its proprietary lead asset in oncology
- Pamela Trail, the company's new CSO, highlights progress focusing the research team in several key areas, with the goal of producing a sustainable pipeline of DARPin® molecule IND candidates
- The company provides additional insight on its immuno-oncology DARPin® toolbox, including MP0310 and a second multi-specific DARPin® molecule
- Allergan reiterates its commitment to abicipar which has shown in phase 3 trials the potential to be the first fixed 12 week anti-VEGF for wet AMD
Zurich-Schlieren, Switzerland, and New York, December 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together with its partner Allergan.
On its R&D Day in New York, entitled "Building Tomorrow's Breakthroughs," the company elaborates on its refined development plans for its most advanced proprietary candidate MP0250 in multiple myeloma (MM). In particular, the company announces its intention to initiate a second phase 2 trial for MP0250 in MM. This complementary trial will recruit patients with relapsed or refractory MM who have failed at least two lines of therapy including a proteasome inhibitor and an immunomodulatory drug (IMiD) and in whom the most recent therapy was IMiD-based. Patients will be treated with MP0250 in combination with Pomalidomide® and dexamethasone. The design of the initial phase 2 trial for MP0250 in MM will be updated to recruit patients with a proteasome inhibitor (PI) based regimen as the most recent therapy. Those patients continue to be dosed with MP0250 in combination with Velcade®and dexamethasone.
Molecular Partners also presents additional preclinical data on MP0310, its most advanced multi-specific (FAP x 4-1BB) DARPin® immuno-oncology compound, which is expected to move into the clinic in 2019. In addition, data on FAP x CD40, a second multi-specific preclinical DARPin® therapeutic in immuno-oncology, will be presented.
"I am pleased to report on our progress in oncology and our efforts to build a sustainable pipeline of DARPin® therapeutics," said Patrick Amstutz, Chief Executive Officer of Molecular Partners.
Pamela A. Trail, Chief Scientific Officer of the company, added: "Our unique DARPin® designs have the potential to translate into novel therapeutics across the landscape of oncology. Going forward, we will focus on several key areas of therapeutic intervention which are in the sweet spot of our DARPin® technology."
In addition to an overview of the Molecular Partners clinical and preclinical pipeline, the R&D Day will feature presentations by the following experts:
- Dr. Robert Orlowski, Chairman, Ad Interim, Director of Myeloma, Professor of Medicine Departments of Lymphoma/Myeloma and Experimental Therapeutics, MD Anderson Cancer Center
- Dr. Yehia Hashad, Vice President and Global Head of Clinical Development, Ophthalmology, Allergan
Logistics
The R&D Day for institutional investors, sell-side analysts, investment bankers, and business development professionals will take place at The Yale Club, 50 Vanderbilt Avenue, New York City, from 11:30 am - 2:30 pm EST. To RSVP email Susan A. Noonan at susan@sanoonan.com.
Attendees are invited to check at 11:30 am EST. The presentations will begin at 12:00 pm, followed by a Q&A session. Lunch will be served.
Audio webcast
A respective audio webcast will be accessible, both live and as a replay, on the investors section of the company's website, along with the accompanying presentation slides.
Financial Calendar
February 7, 2019 | Publication of Full-year Results 2018 (unaudited) |
March 15, 2019 | Expected Publication of Annual Report 2018 |
April 16, 2019 | Annual General Meeting |
May 9, 2019 | Interim Management Statement Q1 2019 |
http://investors.molecularpartners.com/financial-calendar-and-events/
*DARPin® is a registered trademark owned by Molecular Partners AG.
| Provider | Channel | Contact | ||
|---|---|---|---|---|
|
EQS Group Ltd., Switzerland switzerland.eqs.com |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries cs.switzerland@eqs.com +41 41 763 00 50 |
